Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Lalezari

Showing results (101-110 of 128) with videos related to

Pageof 13
Sort By:
Lancet (London, England)|May 27, 1972
Single-lung transplantation in emphysemaF J Veith, S K Koerner, L A Attai, et al.
Nature Medicine|October 15, 2025
Budigalimab, an anti-PD-1 inhibitor, for people living with HIV-1: a randomized, placebo-controlled phase 1b studyMoti N Ramgopal, Jacob P Lalezari, Ana Gabriela Pires Dos Santos, et al.
The Journal of Infectious Diseases|November 15, 2014
Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults Previously Vaccinated With Pneumococcal Polysaccharide VaccineMarshall J Glesby, Wendy Watson, Cynthia Brinson, et al.
The Journal of Infectious Diseases|April 10, 2010
Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibodyJeffrey M Jacobson, Melanie A Thompson, Jacob P Lalezari, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|December 18, 2001
High dose oral ganciclovir treatment for cytomegalovirus retinitisJacob P Lalezari, Dorothy N Friedberg, Jack Bissett, et al.
Annals of Internal Medicine|May 15, 1993
Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapyM A Fischl, R M Olson, S E Follansbee, et al.
Antimicrobial Agents and Chemotherapy|July 28, 2010
Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adultsJeffrey M Jacobson, Jacob P Lalezari, Melanie A Thompson, et al.
AIDS (London, England)|March 21, 2003
A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapyJacob P Lalezari, Joseph J Eron, Margrit Carlson, et al.
The New England Journal of Medicine|March 15, 2003
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South AmericaJacob P Lalezari, Keith Henry, Mary O'Hearn, et al.
The Journal of Infectious Diseases|March 5, 2005
T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimenJacob P Lalezari, Nicholaos C Bellos, Kunthavi Sathasivam, et al.
Pageof 13

Showing results (101-110 of 128) with videos related to

Sort By:
Pageof 13
Lancet (London, England)|May 27, 1972
Single-lung transplantation in emphysemaF J Veith, S K Koerner, L A Attai, et al.
Nature Medicine|October 15, 2025
Budigalimab, an anti-PD-1 inhibitor, for people living with HIV-1: a randomized, placebo-controlled phase 1b studyMoti N Ramgopal, Jacob P Lalezari, Ana Gabriela Pires Dos Santos, et al.
The Journal of Infectious Diseases|November 15, 2014
Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults Previously Vaccinated With Pneumococcal Polysaccharide VaccineMarshall J Glesby, Wendy Watson, Cynthia Brinson, et al.
The Journal of Infectious Diseases|April 10, 2010
Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibodyJeffrey M Jacobson, Melanie A Thompson, Jacob P Lalezari, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|December 18, 2001
High dose oral ganciclovir treatment for cytomegalovirus retinitisJacob P Lalezari, Dorothy N Friedberg, Jack Bissett, et al.
Annals of Internal Medicine|May 15, 1993
Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapyM A Fischl, R M Olson, S E Follansbee, et al.
Antimicrobial Agents and Chemotherapy|July 28, 2010
Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adultsJeffrey M Jacobson, Jacob P Lalezari, Melanie A Thompson, et al.
AIDS (London, England)|March 21, 2003
A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapyJacob P Lalezari, Joseph J Eron, Margrit Carlson, et al.
The New England Journal of Medicine|March 15, 2003
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South AmericaJacob P Lalezari, Keith Henry, Mary O'Hearn, et al.
The Journal of Infectious Diseases|March 5, 2005
T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimenJacob P Lalezari, Nicholaos C Bellos, Kunthavi Sathasivam, et al.
Pageof 13